Nevertheless, the risk of cardiomyopathy linked to CAV3 mutations remains poorly studied, and this assumes clinical relevance when considering improvement in the muscular therapy of young patients with caveolinopathies. This evidence concerns the gene CAV3 and caveolinopathy.